These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 20446825

  • 1. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE, Feldman SR.
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [Abstract] [Full Text] [Related]

  • 2. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 3. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R.
    Value Health; 2011 Jan 14; 14(5):652-6. PubMed ID: 21839402
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH, Del Rosso JQ.
    J Drugs Dermatol; 2009 Jun 14; 8(6):546-59. PubMed ID: 19537380
    [Abstract] [Full Text] [Related]

  • 10. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2009 Mar 14; 160(3):670-5. PubMed ID: 19210502
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Etanercept for the treatment of psoriasis.
    Bissonnette R.
    Skin Therapy Lett; 2006 Feb 14; 11(1):1-4. PubMed ID: 16485060
    [Abstract] [Full Text] [Related]

  • 13. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr 14; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 14. Comparing biological therapies in psoriasis: implications for clinical practice.
    Griffiths CE.
    J Eur Acad Dermatol Venereol; 2010 Oct 14; 24 Suppl 6():10-4. PubMed ID: 20831704
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V, Pérez A, Sánchez JL, Oliver V, Martínez L, Alegre V.
    Actas Dermosifiliogr; 2010 Oct 14; 101(1):47-53. PubMed ID: 20109392
    [Abstract] [Full Text] [Related]

  • 19. Ustekinumab for psoriasis and psoriatic arthritis.
    Goldminz AM, Gottlieb AB.
    J Rheumatol Suppl; 2012 Jul 14; 89():86-9. PubMed ID: 22751602
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.